By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

The S&P 500 index closed higher on Monday as investors were still optimistic over trade talks between the United States and ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...